Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia

The Pharmacogenomics Journal volume 9, pages 311–318 (2009)Cite this article

Abstract

Clinical trial data were evaluated for the association between 22 single-nucleotide polymorphisms (SNPs) and response in acutely ill patients diagnosed with schizophrenia, schizoaffective disorder or schizophreniform disorder, who were treated with oral risperidone. All patients in the exploratory (78 African Americans) and validation (65 whites) data sets received risperidone 2–6 mg per day over 2–12 weeks. Two SNPs were found to have significant associations with response to risperidone over 2–12 weeks in both African-American and white patients and had a consistent direction of effect in both cohorts. Metabotropic glutamate receptor (GRM3) SNP, rs724226, was associated with a change in the positive and negative syndrome scale (PANSS) total response. Catechol-O-methyltransferase (COMT) SNP, rs165599, was moderately associated with a change in the PANSS Negative score. The greater prevalence of poor-responder GRM3 and COMT alleles in white versus African-American patients might have a clinical significance in evaluating the ethnic-specific response to risperidone.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Arranz MJ, de Leon J . Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707–747.

    Article  CAS  PubMed  Google Scholar 

  2. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A . Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 2008; 34: 1163–1171.

    Article  PubMed  Google Scholar 

  3. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008; 102: 230–240.

    Article  PubMed  Google Scholar 

  4. Schäfer M, Rujescu D, Giegling I, Guntermann A, Erfuth A, Bondy B et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene. Am J Psychiatry 2001; 158: 802–804.

    Article  PubMed  Google Scholar 

  5. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N . Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 2003; 3: 356–361.

    Article  CAS  PubMed  Google Scholar 

  6. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP . COMT variants associated with duloxetine response: a candidate gene association analysis of a randomized clinical treatment trial for major depression. Biol Psychiatry 2009; 65: 785–791.

    Article  CAS  PubMed  Google Scholar 

  7. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004; 56: 677–682.

    Article  CAS  PubMed  Google Scholar 

  8. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH . Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol 2004; 7: 461–470.

    Article  CAS  PubMed  Google Scholar 

  9. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006; 163: 529–531.

    Article  PubMed  Google Scholar 

  10. Adams DH, Close S, Farmen M, Downing AM, Breier A, Houston JP . Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominantly Caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol Clin Exp 2008; 23: 267–274.

    Article  CAS  Google Scholar 

  11. Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH . Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005; 25: 6–11.

    Article  CAS  PubMed  Google Scholar 

  12. Bishop JR, Ellingrod VL, Moline J, Miller D . Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 2005; 77: 253–260.

    Article  PubMed  Google Scholar 

  13. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH . Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene. Am J Psychiatry 2002; 159: 1593–1595.

    Article  PubMed  Google Scholar 

  14. Kim B, Choi EY, Kim CY, Song K, Joo YH . Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol Clin Exp 2008; 23: 61–67.

    Article  CAS  Google Scholar 

  15. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J et al. Evidence for association between the polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998; 3: 61–66.

    Article  CAS  PubMed  Google Scholar 

  16. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW et al. Association between clozapine resistance and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7: 169–172.

    Article  CAS  PubMed  Google Scholar 

  17. Lane HY, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH . Risperidone response and 5-HT6 receptor gene variance: Genetic association analysis with adjustment for nongenetic confounders. Schizophr Res 2004; 67: 63–70.

    Article  PubMed  Google Scholar 

  18. Predicting Response to Risperidone Treatment Through Identification of Early-Onset of Antipsychotic Drug Action in Schizophrenia. Approved 30 Jan 2006. ClinicalTrials.gov Identifier: NCT00373321.

  19. Kay SR, Fiszbein A, Opler LA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276.

    Article  CAS  PubMed  Google Scholar 

  20. Jurinke C, van den Boom D, Cantor CR, Koster H . Automated genotyping using the DNA MassArray technology. Methods Mol Biol 2002; 187: 179–192.

    CAS  PubMed  Google Scholar 

  21. Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR . Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441–449.

    Article  PubMed  Google Scholar 

  22. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003; 73: 152–161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296–1302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Chan RC, Chen RY, Chen EY, Hui TC, Cheung EF, Cheung HK et al. The differential clinical and neurocognitive profiles of COMT SNP rs165599 genotypes in schizophrenia. J Int Neuropsychol Soc 2005; 11: 202–204.

    Article  CAS  PubMed  Google Scholar 

  25. Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007; 61: 111–118.

    Article  CAS  PubMed  Google Scholar 

  26. Bishop JR, Ellingrod VL . Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response. Pharmacogenomics 2004; 5: 463–477.

    Article  CAS  PubMed  Google Scholar 

  27. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM . Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160: 2063–2065.

    Article  PubMed  Google Scholar 

  28. Leucht S, Busch R, Kissling W, Kane JM . Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007; 68: 352–360.

    Article  CAS  PubMed  Google Scholar 

  29. Leucht S, Shamsi SA, Busch R, Kissling W, Kane JM . Predicting antipsychotic drug response—replication and extension to six weeks in an international olanzapine study. Schizophr Res 2008; 101: 312–319.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge the assistance of Virginia M Peschke of Medical Communication Consultants in the preparation of this paper.

Author information

Authors and Affiliations

  1. Lilly USA, LLC, Indianapolis, IN, USA

    B A Fijal, V L Stauffer, R R Conley, H H Jamal, M M Witte & J P Houston

  2. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

    B J Kinon

  3. King's College of London, Institute of Psychiatry, London, UK

    S Kapur

  4. Zucker Hillside Hospital, Glen Oaks, NY, USA

    J M Kane

Authors
  1. B A Fijal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B J Kinon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Kapur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V L Stauffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R R Conley
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H H Jamal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J M Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M M Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J P Houston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J P Houston.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fijal, B., Kinon, B., Kapur, S. et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 9, 311–318 (2009). https://doi.org/10.1038/tpj.2009.24

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2009.24

Keywords

Search

Advanced search

Quick links